Expedite your clinical study with a Pre-IND Speed to Study Strategy

Is your drug product manufactured outside of the United States? Do you have challenging dosing milestones?

Implementing a Pre-IND packaging strategy will expedite your upstream timeline to ensure you meet your first patient-in milestones while you await your FDA approval and IND number.

In this recording, Sharlett Burgess (Quality Director of Canada) and Jackie Newell (Business Development Executive) discusses the in’s and out’s of the Pre-IND Speed to Study™ offering, including the quality and regulatory considerations, and how introducing this process into your overall clinical supply strategy will accelerate your trial and attain your FPI milestones.

To download to the recording of this Water Cooler Chat, please complete the form below

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients